An interesting commentary on the interpretation of the Nilotinib trial results – The Science of Parkinson's
Enhanced in vivo targeting of estrogen receptor alpha signaling in murine mammary adenocarcinoma by nilotinib/rosuvastatin novel combination - ScienceDirect
Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma
Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium - Journal of the Neurological Sciences
Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases - ScienceDirect
Tolerance of Tyrosine Kinase Inhibitors among 33 Cancer Patients Followed in CHU Annaba-Algeria
Cells | Free Full-Text | Nilotinib: A Tyrosine Kinase Inhibitor Mediates Resistance to Intracellular Mycobacterium Via Regulating Autophagy | HTML
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. - Abstract - Europe PMC
Chronic Myeloid Leukemia - ppt video online download
Nilotinib - Wikipedia
Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review | SpringerLink
Frontiers | Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation | Oncology
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors - ScienceDirect
Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein | Leukemia
Imatinib - Wikipedia
5MJC BCU 13: Tyrosine Kinases as Targets for Cancer Therapy | Research To Practice
Frontiers | A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease | Cellular Neuroscience
Nilotinib | C28H22F3N7O - PubChem
Modern Therapy of Chronic Myeloid Leukemia | IntechOpen
Schematic representation of the mechanism of action of the BCR-ABLTKIs.... | Download Scientific Diagram
Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer | EMBO Molecular Medicine
Flying under the radar: the new wave of BCR–ABL inhibitors | Nature Reviews Drug Discovery
Scheme explaining the synergistic effects of combining nilotinib and... | Download Scientific Diagram
Third-line therapy for chronic myeloid leukemia: current status and future directions | Journal of Hematology & Oncology | Full Text
Chemical structures of the ATP competitors imatinib, nilotinib,... | Download Scientific Diagram
Pharmacology of Drugs: Nilotinib
